Trial on the efficacy of metformin in the treatment of Non-alcoholic steatohepatitis

Prospective double blind randomized placebo controlled trial on the efficacy of metformin in the treatment of NASH

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2007/002

Enrollment

170

Registered

2007-02-23

Start date

2004-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non - alcoholic steatohepatitis (NASH)

Interventions

Liver biopsy before and after metformin for 6 months

Eligibility

Inclusion criteria

Inclusion criteria: * Patients with clinical, biochemical, radiological and histological evidence of NASH * No history of other possible aetiological factors for steatohepatitis such as significant alcohol consumption, medications

Exclusion criteria

Exclusion criteria: * Patients with diabetes mellitus * Patients with significantly elevated levels of total cholesterol and triglycerides requiring lipid lowering treatment * Patients with severe obesity * Patients with history of significant alcohol ingestion. *patients with history of taking medications known to cause NASH. * Patients with any other liver diseases * Patients with contraindications for metformin * Pregnant females * All patients with contraindications for liver biopsy

Design outcomes

Primary

Measure	Time frame
End of treatment with metformin or placebo for 6 months [at 6 months]	—

Secondary

Measure	Time frame
None [None]	—

Countries

Sri Lanka

Contacts

Public ContactDr Anuradha Dassanayake

Senior Lecturer

anuradhadassanayake@hotmail.com+94 112961157

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026